Deborah Weinstein

Deborah Weinstein has covered politics, crime, and healthcare policies for various news outlets including Medical Marketing & Media, where she specializes in Obesity, Alzheimer’s disease and healthcare costs.

Most Recent Articles by Deborah Weinstein

Five things for pharma marketers to know: Tuesday, September 2

Five things for pharma marketers to know: Tuesday, September 2

Sanofi and Regeneron unveil Phase-III results of their PCSK9; Merck will present data on its anti-PD-1 at the end of this month; WSJ op/ed suggests US should lead fight against Ebola; Novo Nordisk kills inflammatory business unit to shift resources to diabetes and obesity; generics firm Cipla could stand to gain from Advair patent expiry.

Five things for Pharma Marketers to know: Friday, August 29

Five things for Pharma Marketers to know: Friday, August 29

Takeda closes out a good-news, bad-news kind of week, AstraZeneca adds a new clinical trial for its experimental PD-1, and researchers link a funeral to the Ebola outbreak.

Amgen sends PCSK9 to FDA

Amgen sends PCSK9 to FDA

Evolocumab holds the FDA's first filed biologics license application for the class.

Consultants expect M&A tempo to continue

Consultants expect M&A tempo to continue

PwC anticipates that divestitures will fuel late-2014 deals, but notes that the noise around early deals and the financials don't fully match up.

Five things for Pharma Marketers to Know: Thursday, August 28

Five things for Pharma Marketers to Know: Thursday, August 28

Human testing of GSK's Ebola virus starts next week, menopause is a costly healthcare concern, and a small conversation with pharmacists may have a big impact.

More Articles by Deborah Weinstein

Email Newsletters